Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Lannett New York Listing Under Threat As FDA Says No On Advair
Flurry Of Announcements Also Sees Lannett Agree Sale Of Carmel Site
Mar 08 2022
•
By
Dean Rudge
Lannett has 45 days to submit a business plan to the NYSE • Source: Piotr Adamowicz / Alamy Stock Photo
More from Business
More from Generics Bulletin